Verrica Pharmaceuticals Inc.
VRCA
$5.19
-$0.07-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -53.85% | 46.06% | 1,380.23% | 905.39% | 145.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.85% | 46.06% | 1,380.23% | 905.39% | 145.35% |
| Cost of Revenue | 195.38% | 74.53% | 118.68% | 16.69% | -39.39% |
| Gross Profit | -110.13% | -61.84% | 180.81% | 338.69% | 687.39% |
| SG&A Expenses | 16.91% | 12.90% | -17.83% | -41.53% | -46.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.23% | 27.39% | 3.14% | -32.80% | -45.09% |
| Operating Income | -854.90% | -19.50% | 38.68% | 107.86% | 109.93% |
| Income Before Tax | -6,547.55% | 0.62% | 50.17% | 98.80% | 101.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6,547.55% | 0.62% | 50.17% | 98.80% | 101.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6,547.55% | 0.62% | 50.17% | 98.80% | 101.19% |
| EBIT | -854.90% | -19.50% | 38.68% | 107.86% | 109.93% |
| EBITDA | -789.36% | -20.07% | 38.65% | 108.49% | 110.94% |
| EPS Basic | -2,971.63% | 55.76% | 76.22% | 99.41% | 100.58% |
| Normalized Basic EPS | -2,607.46% | 55.76% | 81.37% | 99.41% | 100.58% |
| EPS Diluted | -3,200.00% | 55.76% | 76.22% | 99.41% | 100.54% |
| Normalized Diluted EPS | -2,607.46% | 55.76% | 81.37% | 99.41% | 100.58% |
| Average Basic Shares Outstanding | 124.54% | 124.65% | 109.57% | 102.76% | 104.04% |
| Average Diluted Shares Outstanding | 124.49% | 124.65% | 109.57% | 102.76% | 104.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |